Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.3599 |
---|---|
High | 0.369 |
Low | 0.3022 |
Bid | 0.3152 |
Offer | 0.35 |
Previous close | 0.3701 |
Average volume | 323.32k |
---|---|
Shares outstanding | 35.52m |
Free float | 20.28m |
P/E (TTM) | -- |
Market cap | 13.15m USD |
EPS (TTM) | -3.74 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Announcements
- NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
- NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
- NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
- NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
- NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference
- NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
- NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
More ▼